Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

AbbVie Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (144)
Cancellation by sponsor (94)
Prescription medicine registration (28)
Australian Public Assessment Report (AusPAR) (22)
Prescription medicine evaluation (8)
Designation or determination (7)
Prescription medicine decision summary (2)
Section 14, TGO91 consent (1)

Date

2026 (19)
2025 (28)
2024 (26)
2023 (26)
2022 (12)
2021 (14)
2020 (20)
2019 (22)
2018 (14)
2017 (29)
2016 (5)
2015 (19)
2014 (26)
2013 (4)
2012 (4)
2011 (4)
2010 (4)
2009 (4)
2008 (3)
2007 (1)
2006 (4)
2005 (4)
2002 (2)
2001 (1)
1999 (1)
1998 (1)
1997 (1)
1996 (1)
1994 (2)
1991 (5)

Search

Sponsor content

306 result(s) found, displaying 81 to 90

RINVOQ upadacitinib 45 mg modified release tablet blister pack (375857)

20 September 2022

ARTG

Australian Register of Therapeutic Goods (ARTG) information for RINVOQ upadacitinib 45 mg modified release tablet blister pack.
GENOPTIC gentamicin 3mg/mL (as sulfate) eye drops bottle Cancelled under Section 30(1)(c) of the Act

12 December 2023

Cancellation by sponsor

Requested by Abbvie Pty Ltd
OCUFEN flurbiprofen sodium dihydrate 0.03% eye drops, bottle Cancelled under Section 30(1)(c) of the Act

12 December 2023

Cancellation by sponsor

Requested by Abbvie Pty Ltd
MAVIRET glecaprevir 50 mg / pibrentasvir 20 mg granules sachet (352573)

7 February 2022

ARTG

Australian Register of Therapeutic Goods (ARTG) information for MAVIRET glecaprevir 50 mg / pibrentasvir 20 mg granules sachet.
RINVOQ (Abbvie Pty Ltd)

13 July 2023

Prescription medicine registration

Active ingredients: upadacitinib hemihydrate.
Abbvie Pty Ltd - Medicine administration kit, percutaneous, medicated, single-use (381114)

20 December 2021

ARTG

Australian Register of Therapeutic Goods (ARTG) information for Abbvie Pty Ltd - Medicine administration kit, percutaneous, medicated, single-use.
Abbvie Pty Ltd - Breast implant funnel Cancelled under Section 41GL(d) of the Act

30 June 2023

Cancellation by sponsor

Requested by Abbvie Pty Ltd
Abbvie Pty Ltd - Tissue expander injection port Cancelled under Section 41GL(d) of the Act

30 June 2023

Cancellation by sponsor

Requested by Abbvie Pty Ltd
Abbvie Pty Ltd - Tissue expander injection site locater Cancelled under Section 41GL(d) of the Act

30 June 2023

Cancellation by sponsor

Requested by Abbvie Pty Ltd
Abbvie Pty Ltd - Suction system canister, single-use Cancelled under Section 41GL(d) of the Act

30 June 2023

Cancellation by sponsor

Requested by Abbvie Pty Ltd

Pages

First page
Previous page
…
Page 5
Page 6
Page 7
Page 8
Current page 9
Page 10
Page 11
Page 12
Page 13
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.